Status: Recruiting
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT immunosuppression, to abrogate the need for lifelong immunosuppression, the risk of chronic rejection and, ultimately, the need for repeated transplantation.
Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Age: 1-30Biological sex: AllType: InterventionalSponsor: Alice BertainaUpdated: Jul 17, 2023Locations: 1
Eligibility criteria
Chronic kidney disease (CKD) stage 3 or greater [+5]
Pregnant or lactating females. [+7]